<DOC>
	<DOCNO>NCT00304070</DOCNO>
	<brief_summary>This phase III clinical trial study well cisplatin-based chemotherapy and/or surgery work treat young patient stage I , stage II , stage III stage IV adrenocortical cancer . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving surgery may kill tumor cell remain surgery .</brief_summary>
	<brief_title>Cisplatin-Based Chemotherapy and/or Surgery Treating Young Patients With Adrenocortical Tumor</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Describe outcome patient stage I adrenocortical tumor ( ACT ) treat surgery alone . II . Describe outcome patient stage II ACT treat radical adrenalectomy plus regional retroperitoneal lymph node dissection . III . Describe outcome patient unresectable metastatic ACT treat mitotane cisplatin-based chemotherapy regimen . SECONDARY OBJECTIVES : I . Determine feasibility complication associate use radical adrenalectomy regional node dissection ( RLND ) patient . II . Determine toxicity mitotane administer cisplatin , etoposide , doxorubicin hydrochloride patient residual disease surgery , inoperable tumor , metastatic disease diagnosis . III . Determine , prospectively , frequency tumor spillage surgery patient . IV . Determine frequency lymph node involvement patient . V. Compare incidence type germline p53 mutation non-Brazilian child child Southern Brazil . VI . Characterize cooperate molecular alteration associate ACT . VII . Determine presence embryonal marker child ACT . OUTLINE : STRATUM I ( stage I disease ) : Patients undergo primary tumor resection retroperitoneal lymph node sample follow observation . Patients undergone prior surgery without nodal sample undergo observation . STRATUM II ( stage II disease ) : Patients undergo primary tumor resection extend regional lymph node dissection follow observation . Patients undergone prior surgery simple resection primary tumor undergo exploratory surgery extend regional lymph node dissection follow observation . STRATUM III ( stage III IV disease ) : INDUCTION CHEMOTHERAPY : Patients receive cisplatin-based chemotherapy comprise oral mitotane four time daily day 1-21 ; cisplatin IV 6 hour day 1-2 ; etoposide IV 1 hour day 1-3 ; doxorubicin hydrochloride IV 1 hour day 4-5 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 6 continue blood count recover OR pegfilgrastim SC day 6 . Treatment repeat every 21 day 2-4 course absence disease progression unacceptable toxicity . Patients stable disease partial response proceed surgery . Patients complete response proceed directly continuation chemotherapy . SURGERY : Patients stage III disease undergo extend surgery regional lymph node dissection . Patients stage IV disease undergo primary tumor resection ( feasible ) regional lymph node dissection resection metastasis . Patients proceed continuation chemotherapy . CONTINUATION CHEMOTHERAPY : Patients receive additional cisplatin-based chemotherapy ( induction chemotherapy ) 4-6 course follow mitotane alone additional 2 month . Patients stage IV disease proceed additional surgery feasible . ADDITIONAL SURGEY : Patients stage IV disease may undergo additional primary tumor resection regional lymph node dissection resection ( re-resection ) metastasis . After completion study treatment , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Adrenal Cortex Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitotane</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm adrenocortical carcinoma Newly diagnose disease within past 3 week Any disease stage allow Lansky performance status 60100 % ( patient ≤ 16 year old ) Karnofsky performance status 60100 % ( patient &gt; 16 year old ) Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base age follow : 0.4 mg/dL ( 1 month &lt; 6 month ) 0.5 mg/dL ( 6 month &lt; 1 year age ) 0.6 mg/dL ( 1 &lt; 2 year age 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( ≥ 16 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 50 % radionuclide angiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No previous chemotherapy adrenocortical carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>